Infusion is usually outpatient with 1–2 days rest. Any cognitive stabilisation, if it occurs, unfolds over weeks to months. Patients typically continue approved medications and may begin amyloid-targeting antibodies during or after. There is no period in which Alzheimer's reverses; decline is expected to continue, with possible slowing of rate.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Am I a candidate? → · Alzheimer's Disease: full overview → · Alzheimer's Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită